1928 related articles for article (PubMed ID: 18571246)
1. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.
Pinheiro Edos S; Antunes OA; Fortunak JM
Antiviral Res; 2008 Sep; 79(3):143-65. PubMed ID: 18571246
[TBL] [Abstract][Full Text] [Related]
2. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
[TBL] [Abstract][Full Text] [Related]
3. AIDS in the Third World: how to stop the HIV infection?
De Clercq E
Verh K Acad Geneeskd Belg; 2007; 69(2):65-80. PubMed ID: 17550059
[TBL] [Abstract][Full Text] [Related]
4. The history of antiretrovirals: key discoveries over the past 25 years.
De Clercq E
Rev Med Virol; 2009 Sep; 19(5):287-99. PubMed ID: 19714702
[TBL] [Abstract][Full Text] [Related]
5. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV.
De Clercq E
Int J Antimicrob Agents; 2009 Apr; 33(4):307-20. PubMed ID: 19108994
[TBL] [Abstract][Full Text] [Related]
6. Anti-HIV drugs.
De Clercq E
Verh K Acad Geneeskd Belg; 2007; 69(2):81-104. PubMed ID: 17550060
[TBL] [Abstract][Full Text] [Related]
7. Examining the production costs of antiretroviral drugs.
Pinheiro E; Vasan A; Kim JY; Lee E; Guimier JM; Perriens J
AIDS; 2006 Aug; 20(13):1745-52. PubMed ID: 16931939
[TBL] [Abstract][Full Text] [Related]
8. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails.
Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Piyavong B; Chumpathat N; Chantratita W
Clin Infect Dis; 2007 Feb; 44(3):447-52. PubMed ID: 17205457
[TBL] [Abstract][Full Text] [Related]
9. Tenofovir: new indication. For first-line antiretroviral therapy: wait and see.
Prescrire Int; 2004 Oct; 13(73):180-2. PubMed ID: 15499699
[TBL] [Abstract][Full Text] [Related]
10. New anti-HIV agents and targets.
De Clercq E
Med Res Rev; 2002 Nov; 22(6):531-65. PubMed ID: 12369088
[TBL] [Abstract][Full Text] [Related]
11. Use of antiretroviral therapy in resource-limited countries in 2006: distribution and uptake of first- and second-line regimens.
Renaud-Théry F; Nguimfack BD; Vitoria M; Lee E; Graaff P; Samb B; Perriëns J
AIDS; 2007 Jul; 21 Suppl 4():S89-95. PubMed ID: 17620758
[TBL] [Abstract][Full Text] [Related]
12. Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières.
Pujades-Rodríguez M; O'Brien D; Humblet P; Calmy A
AIDS; 2008 Jul; 22(11):1305-12. PubMed ID: 18580610
[TBL] [Abstract][Full Text] [Related]
13. Companies reduce prices for HIV drugs in developing countries.
Gottlieb S
Bull World Health Organ; 2000; 78(6):862. PubMed ID: 10916926
[TBL] [Abstract][Full Text] [Related]
14. Evolution of antiretroviral drug costs in Brazil in the context of free and universal access to AIDS treatment.
Nunn AS; Fonseca EM; Bastos FI; Gruskin S; Salomon JA
PLoS Med; 2007 Nov; 4(11):e305. PubMed ID: 18001145
[TBL] [Abstract][Full Text] [Related]
15. Forecast of demand for antiretroviral drugs in low and middle-income countries: 2007-2008.
Galárraga O; O'Brien ME; Gutiérrez JP; Renaud-Théry F; Nguimfack BD; Beusenberg M; Waldman K; Soni A; Bertozzi SM; Greener R
AIDS; 2007 Jul; 21 Suppl 4():S97-103. PubMed ID: 17620759
[TBL] [Abstract][Full Text] [Related]
16. API consensus guidelines for use of antiretroviral therapy in adults (API-ART guidelines). Endorsed by the AIDS Society of India.
Gupta SB; Pujari SN; Joshi SR; Patel AK;
J Assoc Physicians India; 2006 Jan; 54():57-74. PubMed ID: 16649742
[TBL] [Abstract][Full Text] [Related]
17. New antiretrovirals and new combinations.
Havlir DV; Lange JM
AIDS; 1998; 12 Suppl A():S165-74. PubMed ID: 9632999
[TBL] [Abstract][Full Text] [Related]
18. First-line antiretroviral treatment of HIV-infected children. A choice largely based on adult data.
Prescrire Int; 2011 Apr; 20(115):101-4. PubMed ID: 21648216
[TBL] [Abstract][Full Text] [Related]
19. [Characteristics of antiretroviral drugs].
Ribera E; Tuset M; Martín M; del Cacho E
Enferm Infecc Microbiol Clin; 2011 May; 29(5):362-91. PubMed ID: 21531048
[TBL] [Abstract][Full Text] [Related]
20. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis.
Witvrouw M; Pannecouque C; Switzer WM; Folks TM; De Clercq E; Heneine W
Antivir Ther; 2004 Feb; 9(1):57-65. PubMed ID: 15040537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
